HLB Advances Liver Cancer Drug Rivoceranib Towards FDA Approval After Manufacturing Site Clearance

HLB is moving forward with its application for U.S. Food and Drug Administration (FDA) approval of the liver cancer drug rivoceranib, following the successful clearance of a second manufacturing site during routine current good manufacturing practice (cGMP) inspections. This development addresses previous manufacturing concerns that had led to multiple Complete Response Letters (CRLs) and is expected to accelerate the drug's launch timeline.